Abbott’s Cancerguard Test Shows Multi-Biomarker Advantage in Early Cancer Detection
Event summary
- Abbott presented new data at AACR 2026 showing its Cancerguard test combines methylation and protein biomarkers to improve early-stage cancer detection.
- A prospectively collected case-control study found 47.1% of positive cancer signals were driven by methylation alone, with additional detection from protein-only (7.4%) and combined signals (45.5%).
- The AACR Cancer Prevention Research Award recognized a 2024 publication on multi-year outcomes from the DETECT-A study, showing all patients treated for stage I or II cancers remained alive and cancer-free after a median follow-up of approximately four years.
- Cancerguard is the only commercially available MCED test designed with a multi-biomarker class approach.
The big picture
Abbott’s advancements in multi-cancer early detection (MCED) come as the healthcare industry increasingly focuses on preventive care and early intervention. The combination of methylation and protein biomarkers in the Cancerguard test addresses a critical gap in cancer screening, particularly for the nearly 70% of cancers that lack recommended screening options. The recognition of the DETECT-A study’s long-term outcomes further strengthens the clinical evidence supporting MCED, positioning Abbott as a leader in this rapidly evolving field.
What we're watching
- Regulatory Approval
- Whether the Cancerguard test will gain FDA clearance or approval from other regulatory authorities, which is currently pending.
- Market Adoption
- The pace at which Cancerguard will be adopted in clinical practice, particularly for cancers lacking guideline-recommended screening options.
- Competitive Positioning
- How Abbott will differentiate Cancerguard from competitors like Exact Sciences Corporation, especially as multi-cancer early detection tests become more common.
Related topics